MA39441A1 - Composition d'insuline a action rapide - Google Patents

Composition d'insuline a action rapide

Info

Publication number
MA39441A1
MA39441A1 MA39441A MA39441A MA39441A1 MA 39441 A1 MA39441 A1 MA 39441A1 MA 39441 A MA39441 A MA 39441A MA 39441 A MA39441 A MA 39441A MA 39441 A1 MA39441 A1 MA 39441A1
Authority
MA
Morocco
Prior art keywords
fast
acting insulin
insulin composition
insulin analog
composition
Prior art date
Application number
MA39441A
Other languages
English (en)
Inventor
Micheal Edward Christe
Thomas Andrew Hardy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53189204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39441(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39441A1 publication Critical patent/MA39441A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur une composition d'insuline humaine ou d'analogue d'insuline qui comprend du tréprostinil et qui possède une action pharmacocinétique plus rapide par rapport aux formulations commerciales de produits analogues d'insuline existants.
MA39441A 2014-05-08 2015-05-04 Composition d'insuline a action rapide MA39441A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461990402P 2014-05-08 2014-05-08
PCT/US2015/029010 WO2015171484A1 (fr) 2014-05-08 2015-05-04 Compositions d'insuline à action rapide

Publications (1)

Publication Number Publication Date
MA39441A1 true MA39441A1 (fr) 2017-06-30

Family

ID=53189204

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39441A MA39441A1 (fr) 2014-05-08 2015-05-04 Composition d'insuline a action rapide

Country Status (36)

Country Link
US (2) US9439952B2 (fr)
EP (3) EP3140008B1 (fr)
JP (1) JP6050902B2 (fr)
KR (1) KR101858890B1 (fr)
CN (1) CN106456717B (fr)
AP (1) AP2016009525A0 (fr)
AR (1) AR100155A1 (fr)
AU (1) AU2015256355B2 (fr)
BR (1) BR112016024357B1 (fr)
CA (1) CA2945188C (fr)
CL (1) CL2016002772A1 (fr)
CY (2) CY1121669T1 (fr)
DK (2) DK3536380T3 (fr)
EA (1) EA031134B1 (fr)
ES (2) ES2733639T3 (fr)
HR (2) HRP20190777T1 (fr)
HU (2) HUE055742T2 (fr)
IL (1) IL248350B (fr)
JO (1) JO3624B1 (fr)
LT (2) LT3536380T (fr)
MA (1) MA39441A1 (fr)
ME (1) ME03384B (fr)
MX (1) MX367521B (fr)
NZ (1) NZ724919A (fr)
PE (1) PE20161408A1 (fr)
PH (1) PH12016502195A1 (fr)
PL (2) PL3140008T3 (fr)
PT (2) PT3140008T (fr)
RS (2) RS58726B1 (fr)
SG (1) SG11201608424WA (fr)
SI (2) SI3140008T1 (fr)
TN (1) TN2016000443A1 (fr)
TR (1) TR201906843T4 (fr)
TW (1) TWI685348B (fr)
UA (1) UA124919C2 (fr)
WO (1) WO2015171484A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (fr) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Promédicaments de tréprostinil
US20180221385A1 (en) * 2015-07-28 2018-08-09 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
IL260823B2 (en) * 2016-01-29 2024-08-01 Mannkind Corp Dry powder inhaler
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
WO2018058124A1 (fr) 2016-09-26 2018-03-29 United Therapeutics Corporation Promédicaments de tréprostinil
EP4265296A3 (fr) 2016-09-29 2023-12-20 Arecor Limited Composition pharmaceutique comprenant des composés de l'insuline
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
CA3065308C (fr) * 2017-06-01 2022-05-17 Eli Lilly And Company Compositions d'insuline a action rapide
JP7465813B2 (ja) 2018-04-04 2024-04-11 アレコル リミテッド インスリン化合物の送達のための医療用注入ポンプシステム
EP3773474B1 (fr) 2018-04-04 2026-01-07 Arecor Limited Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
EP3773473B1 (fr) 2018-04-04 2026-07-01 Arecor Limited Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
CN112739679B (zh) 2018-09-18 2024-03-12 伊莱利利公司 曲前列环素的特丁胺盐
US10799564B1 (en) * 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
CN114096269B (zh) * 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
CN114616225A (zh) 2019-08-23 2022-06-10 联合治疗公司 曲前列环素前药
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
IL296567A (en) 2020-04-17 2022-11-01 United Therapeutics Corp Terfostinil for use in the treatment of interstitial lung disease
AU2021289336B2 (en) 2020-06-09 2025-08-28 Mannkind Corporation Fumaryl diketopiperidine prodrugs of treprostinil
CN115697379A (zh) * 2020-06-30 2023-02-03 江苏恒瑞医药股份有限公司 速效胰岛素组合物及其医药用途
KR102849520B1 (ko) 2020-12-14 2025-08-25 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법
WO2022187352A1 (fr) 2021-03-03 2022-09-09 United Therapeutics Corporation Composition de poudre sèche de treprostinil et son promédicament et comprenant en outre de l'(e)-3,6-bis[4-(n-carbonyl-2-propényl)amidobutyl]-2,5-dicétopipérazine (fdkp)
EP4516297A4 (fr) * 2022-04-29 2026-02-25 Zhaoke pharmaceutical guangzhou co ltd Brume douce de tréprostinil à inhaler
US20240067957A1 (en) * 2022-08-22 2024-02-29 Massachusetts Institute Of Technology Autocatalytic base editing for rna-responsive translational control

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
JPH10251146A (ja) * 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
WO2003020201A2 (fr) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-melanges de polypeptide glp-1 et d'insuline basale
WO2003094956A1 (fr) * 2002-05-07 2003-11-20 Novo Nordisk A/S Preparations solubles comprenant de l'insuline monomere et de l'insuline acylee
DE602005020269D1 (de) * 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
CA2697057A1 (fr) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapie pour complications du diabete
US9387033B2 (en) 2008-08-28 2016-07-12 Roche Diabetes Care, Inc. Device and method for enhanced subcutaneous insulin absorption
EP2330893A4 (fr) * 2008-09-25 2013-01-09 Aradigm Corp Administration pulmonaire profonde de tréprostinil
ES2543705T3 (es) 2009-06-26 2015-08-21 Novo Nordisk A/S Preparación que contiene insulina, nicotinamida y arginina
KR101701943B1 (ko) * 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
KR20140030125A (ko) 2010-12-14 2014-03-11 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
BR112014003225A2 (pt) * 2011-08-12 2017-03-01 Ascendis Pharma As profármacos de treprostinil ligados a veículo
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
WO2015120457A1 (fr) 2014-02-10 2015-08-13 Biodel Inc. Formulations d'insuline à action ultrarapide stabilisées

Also Published As

Publication number Publication date
PT3536380T (pt) 2021-09-02
RS62291B1 (sr) 2021-09-30
TW201625291A (zh) 2016-07-16
HRP20190777T1 (hr) 2019-08-23
CY1124454T1 (el) 2022-07-22
WO2015171484A1 (fr) 2015-11-12
US9439952B2 (en) 2016-09-13
EP3536380A1 (fr) 2019-09-11
TR201906843T4 (tr) 2019-05-21
JO3624B1 (ar) 2020-08-27
EA201691911A1 (ru) 2017-02-28
PT3140008T (pt) 2019-06-25
HUE055742T2 (hu) 2021-12-28
TN2016000443A1 (en) 2018-04-04
EP3536380B8 (fr) 2021-09-22
RS58726B1 (sr) 2019-06-28
SI3536380T1 (sl) 2021-09-30
ES2733639T3 (es) 2019-12-02
PL3536380T3 (pl) 2021-12-27
CY1121669T1 (el) 2020-07-31
AR100155A1 (es) 2016-09-14
TWI685348B (zh) 2020-02-21
LT3536380T (lt) 2021-08-10
SG11201608424WA (en) 2016-11-29
IL248350B (en) 2020-03-31
DK3536380T3 (da) 2021-08-02
US20160129087A1 (en) 2016-05-12
JP6050902B2 (ja) 2016-12-21
AP2016009525A0 (en) 2016-10-31
SI3140008T1 (sl) 2019-06-28
AU2015256355A1 (en) 2016-10-27
PH12016502195B1 (en) 2017-02-06
US20160367640A1 (en) 2016-12-22
KR101858890B1 (ko) 2018-05-16
NZ724919A (en) 2018-01-26
CN106456717A (zh) 2017-02-22
EP3536380B1 (fr) 2021-07-07
EA031134B1 (ru) 2018-11-30
MX2016014643A (es) 2017-03-06
KR20160133567A (ko) 2016-11-22
ES2891983T3 (es) 2022-02-01
PL3140008T3 (pl) 2019-09-30
DK3140008T3 (da) 2019-06-24
IL248350A0 (en) 2016-11-30
AU2015256355B2 (en) 2017-09-14
CA2945188A1 (fr) 2015-11-12
PH12016502195A1 (en) 2017-02-06
EP3140008A1 (fr) 2017-03-15
BR112016024357A2 (pt) 2017-10-10
HRP20211415T1 (hr) 2021-12-10
LT3140008T (lt) 2019-05-27
CA2945188C (fr) 2018-12-11
CL2016002772A1 (es) 2017-06-09
PE20161408A1 (es) 2016-12-28
EP3140008B1 (fr) 2019-04-17
UA124919C2 (uk) 2021-12-15
CN106456717B (zh) 2020-01-17
BR112016024357B1 (pt) 2022-08-23
US10172922B2 (en) 2019-01-08
EP3943155A1 (fr) 2022-01-26
HUE044370T2 (hu) 2019-10-28
JP2016523807A (ja) 2016-08-12
MX367521B (es) 2019-08-26
ME03384B (fr) 2020-01-20

Similar Documents

Publication Publication Date Title
PH12016502195A1 (en) Rapid- acting insulin compositions
MX379267B (es) Composiciones de insulina de rapida accion.
MA41188B1 (fr) Compositions d'insuline à action rapide
SG10201809457YA (en) Insulin receptor partial agonists
MX2017010389A (es) Proteasa de cisteina.
MX2017010390A (es) Proteasa de cisteina.
PH12015502331A1 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
NZ728662A (en) A process for purification of rhu-gcsf
MY190102A (en) Tolerogenic dna vaccine
EP3844279A4 (fr) Produits et compositions
BR112017012524A2 (pt) composição contendo éster parcial de carboidrato
SA519410672B1 (ar) تركيبات إنسولين سريعة المفعول
IL262729A (en) Compositions and methods of providing thyroid hormone or analogs thereof
BR112017024395A2 (pt) aplicador por spray de maior alcance
TH1501004860A (th) อินซูลินอะนาล็อก (insulin analog) ใหม่ และการใช้ของมัน